Published May 23, 2024 | Version v1
Dataset Open

Quantification of ADHD Medication in Biological Fluids with Liquid Chromatography: A Comprehensive Review - Metadata

Authors/Creators

  • 1. ROR icon Vrije Universiteit Brussel
  • 2. Experimental Pharmacology (EFAR)
  • 3. Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information

Contributors

Project leader:

  • 1. Experimental Pharmacology (EFAR), Department of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Vrije Universiteit Brussel (VUB), Jette, Belgium
  • 2. Centre for Environmental Sciences, Hasselt University, Diepenbeek, Belgium
  • 3. Department of Analytical Chemistry, Applied Chemometrics and Molecular Modelling, Vrije Universiteit Brussel (VUB), Jette, Belgium

Description

This file is the metadata related to the publication "Quantification of ADHD Medication in Biological Fluids with Liquid Chromatography: A Comprehensive Review".

Files

Files (265.8 kB)

Name Size Download all
md5:e4930469ecd63dae8ebf0361caa04bcb
265.8 kB Download

Additional details

Identifiers

DOI
10.5281/zenodo.11244184

Related works

Has metadata
Dataset: 10.5281/zenodo.1124418 (DOI)

Dates

Submitted
2024-05-23

References

  • American Psychiatric Association. Diagnostic and Statistical Mannual of Mental Disorders, Fifth Edition. 2013; Josep Antoni Ramos-Quiroga Alonso Montoya AKWD, Sobanski E. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines. Curr Med Res Opin. 2013;29(9):1093–104. Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry. 2019;56:14–34. Sibley MH, Mitchell JT, Becker SP. Method of adult diagnosis influences estimated persistence of childhood ADHD: a systematic review of longitudinal studies. Lancet Psychiatry. 2016;3(12):1157–65. Faraone S V., Banaschewski T, Coghill D, Zheng Y, Biederman J, Bellgrove MA, et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021;128(June 2020):789–818. Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, et al. Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021;35(6):643–53. Hanley GE, Mintzes B. Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. BMC Pregnancy Childbirth. 2014;14(1):1–12. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010:a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23(5):526–33. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010–2019. Eur J Clin Pharmacol. 2023;79(1):173–80. Anderson KN, Ailes EC, Danielson M, Lind JN, Farr SL, Broussard CS, et al. Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15–44 Years — United States, 2003–2015. MMWR Morb Mortal Wkly Rep. 2018;67(2):66–70. Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN, et al. ADHD Medication Use During Pregnancy and Risk for Selected Birth Defects: National Birth Defects Prevention Study, 1998-2011. J Atten Disord. 2020;24(3):479–89. Walsh CJ, Rosenberg SL, Hale EW. Obstetric complications in mothers with ADHD. Frontiers in Reproductive Health. 2022;4(November):1–10. Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. pregnancy-related and offspring outcomes : A systematic review. 2021;34(7):731–47. Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill R V., Reif A. Parental ADHD in pregnancy and the postpartum period – A systematic review. Neurosci Biobehav Rev. 2021;124(September 2020):63–77. Ornoy A, Koren G. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review. Curr Neuropharmacol. 2020;19(11):1794–804. Baker AS, Freeman MP. Management of Attention Deficit Hyperactivity Disorder During Pregnancy. Obstet Gynecol Clin North Am. 2018;45(3):495–509. Andrade C. Risk of major congenital malformations associated with the use of methylphenidate or amphetamines in pregnancy. Journal of Clinical Psychiatry. 2018;79(1). Mohamed Abdulhakim LVR, Michiel W. van Kernebeek NV, Liesbeth Santermans TH, Crunelle FM& CL. Risico's bij gebruik van illegale middelen tijdens de zwangerschap. Verslaving Herstel, Zwangerschap deel 1 Deel 2. 2022;2(1):12–7. Jiang H yin, Zhang X, Jiang C ming, Fu H bin. Maternal and neonatal outcomes after exposure to ADHD medication during pregnancy: A systematic review and meta-analysis. Pharmacoepidemiol Drug Saf. 2019;28(3):288–95. Koren G, Barer Y, Ornoy A. Fetal safety of methylphenidate—A scoping review and meta analysis. Reproductive Toxicology. 2020 Apr;93:230–4. Besag FMC. ADHD treatment and pregnancy. Drug Saf. 2014;37(6):397–408. UNICEF. Breastfeeding [Internet]. [cited 2024 Jan 26]. Available from: https://data.unicef.org/topic/nutrition/breastfeeding/#status Srinivas C, Karlstad Ø, Stigum H, Furu K, Cesta CE, Reutfors J, et al. Trajectories of ADHD medication use before, during, and after pregnancy: A population-based study from Norway and Sweden. Pharmacoepidemiol Drug Saf. 2023;32(10):1152–60. Cohen JM, Srinivas C, Furu K, Cesta CE, Reutfors J, Karlstad Ø. Prevalence trends and individual patterns of ADHD medication use in pregnancy in Norway and Sweden, 2010–2019. Eur J Clin Pharmacol [Internet]. 2023;79(1):173–80. Available from: https://doi.org/10.1007/s00228-022-03428-6 WHO | Exclusive breastfeeding for six months best for babies everywhere. WHO. 2011; Marraccini ME, Weyandt LL, Gudmundsdottir BG, Oster DR, McCallum A. Attention-Deficit Hyperactivity Disorder: Clinical Considerations for Women. J Midwifery Womens Health. 2017 Nov;62(6):684–95. Collin-Lévesque L, El-Ghaddaf Y, Genest M, Jutras M, Leclair G, Weisskopf E, et al. Infant Exposure to Methylphenidate and Duloxetine during Lactation. Breastfeeding Medicine. 2018;13(3):221–5. Hackett L, Ilett K, Kristensen J, Kohan R, Hale T. Infant Dose And Safety Of Breastfeeding For Dexamphetamine And Methylphenidate In Mothers With Attention Deficit Hyperactivity Disorder: 40. Therapeutic Drug Monitoring - THER DRUG MONIT. 2005;27:220–1. Spigset O, Brede WR, Zahlsen K. Excretion of methylphenidate in breast milk. Am J Psychiatry. 2007;164(2):348. Ilett KF, Hackett LP, Kristensen JH, Kohan R. Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol. 2007;63(3):371–5. Boutroy MJ, Gisonna CR, Legagneur M. Clonidine: placental transfer and neonatal adaption. Early Hum Dev. 1988 Aug 1;17(1):275–86. A L Hartikainen-Sorri JEHMK. Pharmacokinetics of clonidine during pregnancy and nursing. Obstetrics & Gynecology [Internet]. 1987 [cited 2024 Mar 19];69(4):598–600. Available from: https://pubmed.ncbi.nlm.nih.gov/3822302/ Sevrez C, Lavocat MP, Mounier G, Elefant E, Magnin S, Teyssier G, et al. Transplacental or breast milk intoxication to clonidine: a case of neonatal hypotonia and drowsiness. Arch Pediatr [Internet]. 2014 Feb [cited 2024 Mar 19];21(2):198–200. Available from: https://pubmed.ncbi.nlm.nih.gov/24411570/ Linda H Chaudron CJS. Bupropion Levels in Breast Milk fir 4 Mother-Infant Pairs: More Answers to Lingering Questions. Journal of Clinical Psychiatry. 2009;70(2y):297–8. Haas JS, Kaplan CP, Barenboim D, Jacob P, Benowitz NL. Bupropion in breast milk: An exposure assessment for potential treatment to prevent post-partum tobacco use. Tob Control. 2004;13(1):52–6. Briggs GG, Samson JH, Ambrose PJ, Schroeder DH. Excretion of Bupropion in Breast Milk. Annals of Pharmacotherapy. 1993;27(4):431–3. Chaudron LH, Schoenecker CJ. Bupropion and breastfeeding: A case of a possible infant seizure. Journal of Clinical Psychiatry. 2004;65(6):881–2. Maddadi S, Qomi M, Rajabi M. Extraction, preconcentration, and determination of methylphenidate in urine sample using solvent bar microextraction in combination with HPLC–UV: Optimization by experimental design. J Liq Chromatogr Relat Technol. 2017 Sep 14;40(15):806–12. Miraee SN, Qomi M, Shamshiri F, Raoufi P. Hollow-Fiber liquid-phase Microextraction Followed by High Performance Liquid Chromatography for the Determination of Trace Amounts of Methylphenidate Hydrochloride in Biological Fluids. Biomedical and Pharmacology Journal. 2014;7(2):715–25. Taghvimi A, Jahed FS, Dastmalchi S, Javadzadeh Y. Clinical Application Study of Polymeric Nanospheres Network in Methylphenidate Extraction from Urine Samples by Dispersive Solid Phase Extraction Adsorbent. Adv Pharm Bull [Internet]. 2022;12(3):561–7. Available from: https://doi.org/10.34172/apb.2022.054 Gandhi A, Beekman C, Parker R, Fang L, Babiskin A, Matta MK. Novel and rapid LC-MS/MS method for quantitative analysis of methylphenidate in dried blood spots. Bioanalysis. 2018;10(11):839–50. Smith CR, Swortwood MJ. Chiral separation and quantification of d,l-methylphenidate, d,l-ethylphenidate and ritalinic acid in blood by LC-MS/MS. Forensic Chemistry [Internet]. 2022;27(November 2021):100400. Available from: https://doi.org/10.1016/j.forc.2022.100400 Patrick KS, Williard RL, VanWert AL, Dowd JJ, Oatis JE, Middaugh LD. Synthesis and pharmacology of ethylphenidate enantiomers: The human transesterification metabolite of methylphenidate and ethanol. J Med Chem. 2005 Apr 21;48(8):2876–81. Mulet CT, Arroyo-Mora LE, Leon LA, Gnagy E, DeCaprio AP. Rapid quantitative analysis of methylphenidate and ritalinic acid in oral fluid by liquid chromatography triple quadrupole mass spectrometry (LC-QqQ-MS). J Chromatogr B Analyt Technol Biomed Life Sci [Internet]. 2018;1092(June):313–9. Available from: https://doi.org/10.1016/j.jchromb.2018.06.025 Herbrink M, Thijssen B, Hillebrand MJX, Rosing H, Schellens JHM, Nuijen B, et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of Dexamphetamine in human plasma. J Pharm Biomed Anal. 2018 Jan 30;148:259–64. El-Beqqali A, Andersson LI, Jeppsson AD, Abdel-Rehim M. Molecularly imprinted polymer-sol-gel tablet toward micro-solid phase extraction: II. Determination of amphetamine in human urine samples by liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 15;1063:130–5. Comiran E, Barreto F, Meneghini LZ, Carlos G, Fröehlich PE, Limberger RP. Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC–MS/MS. Biomedical Chromatography. 2017;31(3):1–8. Rizea-Savu S, Duna SN, Panagiotopoulos D, Sandulovici RC. Single Dose Comparative Bioavailability Study of Lisdexamfetamine Dimesylate as Oral Solution Versus Reference Hard Capsules in Healthy Volunteers. Front Pharmacol. 2022 Apr 5;13. Comiran E, Barreto F, Meneghini LZ, Carlos G, Fröehlich PE, Limberger RP. Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC–MS/MS. Biomedical Chromatography. 2017;31(3):1–8. Thevis M, Sigmund G, Thomas A, Vogel M, Walpurgis K, Kwiatkowska D, et al. Isotope-dilution mass spectrometric quantification of the prodrug lisdexamfetamine in human urine in doping control analysis. Rapid Communications in Mass Spectrometry. 2014 Apr 15;28(7):781–6. Hädener M, Bruni PS, Weinmann W, Frübis M, König S. Accelerated quantification of amphetamine enantiomers in human urine using chiral liquid chromatography and on-line column-switching coupled with tandem mass spectrometry. Anal Bioanal Chem. 2017 Feb 1;409(5):1291–300. Chermá MD, Nilsson GH, Johansson A, Jönsson AK, Ahlner J. Use of Lisdexamfetamine or Amphetamine? Interpretation of Chiral Amphetamine Analyses. J Anal Toxicol. 2022 Jan 1;46(1):10–6. Böttcher M, Kühne D, Beck O. Compliance testing of patients in ADHD treatment with lisdexamphetamine (Elvanse®) using oral fluid as specimen. Clinical Mass Spectrometry. 2019 Nov 1;14:99–105. Leis HJ, Fauler G, Windischhofer W. Enantioselective quantitative analysis of amphetamine in human plasma by liquid chromatography/high-resolution mass spectrometry. Anal Bioanal Chem. 2014;406(18):4473–80. Ruppert K, Geffert C, Clement HW, Bachmann C, Haberhausen M, Schulz E, et al. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study. J Neural Transm. 2022 Jul 1;129(7):945–59. Teichert J, Rowe JB, Ersche KD, Skandali N, Sacher J, Aigner A, et al. Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. Int J Clin Pharmacol Ther. 2020 Aug 1;58(8):426–38. Xia Y, Guo HL, Hu YH, Long JY, Chen J, Chen F, et al. Determination of atomoxetine levels in human plasma using LC-MS/MS and clinical application to Chinese children with ADHD based on CPIC guidelines. Analytical Methods. 2021 Jun 7;13(21):2434–41. Monfort A, Jutras M, Martin B, Boucoiran I, Ferreira E, Leclair G. Simultaneous quantification of 19 analytes in breast milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS). J Pharm Biomed Anal. 2021;204. Jinying Wang QZ. Development and Validation of A High-Performance Liquid Chromatography-Mass Spectroscopy Assay for the Bioequivalence Study of Guanfacine Extended Release (GXR) Tablet in Human Plasma. Current Pharmacuetical Analysis. 2022;18:871–80. Zhuang J, Chen J, Wang X, Pang Y, Bi H, Huang L, et al. Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. Biomedical Chromatography. 2015 Oct 1;29(10):1506–13. Danafar H, Hamidi M. LC-MS Method for Studying the Pharmacokinetics and Bioequivalence of Clonidine Hydrochloride in Healthy Male Volunteers. Vol. 8. Stegmann B, Dörfelt A, Haen E. Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC with Fluorescence Detection. Ther Drug Monit. 2016;38(1):98–107. Smith CR, Swortwood MJ. Analysis of methylphenidate, ethylphenidate, lisdexamfetamine, and amphetamine in oral fluid by liquid chromatography-tandem mass spectrometry. J Forensic Sci. 2022 Mar 1;67(2):669–75. Kwon W, Suh S, In MK, Kim JY. Simultaneous determination of methylphenidate, Amphetamine and their metabolites in urine using direct injection liquid chromatography-tandem mass spectrometry. Mass Spectrometry Letters. 2014 Dec 1;5(4):104–9. Ruppert K, Geffert C, Clement HW, Bachmann C, Haberhausen M, Schulz E, et al. Therapeutic drug monitoring of atomoxetine in children and adolescents with attention-deficit/ hyperactivity disorder: a naturalistic study. J Neural Transm. 2022 Jul 1;129(7):945–59. Teichert J, Rowe JB, Ersche KD, Skandali N, Sacher J, Aigner A, et al. Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. Int J Clin Pharmacol Ther. 2020 Aug 1;58(8):426–38. Coache D, Friciu M, Gaelle Roullin V, Boule M, Forest JM, Leclair G. Stability evaluation of compounded clonidine hydrochloride oral liquids based on a solidphase extraction HPLC-UV method. PLoS One. 2021 Nov 1;16(11). De Nicolò A, Avataneo V, Rabbia F, Sciandra M, Tosello F, Cusato J, et al. UHPLC–MS/MS method with sample dilution to test therapeutic adherence through quantification of ten antihypertensive drugs in urine samples. J Pharm Biomed Anal. 2017 Aug 5;142:279–85. De Nicolò A, Avataneo V, Rabbia F, Bonifacio G, Cusato J, Tomasello C, et al. UHPLC–MS/MS method with protein precipitation extraction for the simultaneous quantification of ten antihypertensive drugs in human plasma from resistant hypertensive patients. J Pharm Biomed Anal. 2016 Sep 10;129:535–41. Avataneo V, Fanelli E, De Nicolò A, Rabbia F, Palermiti A, Pappaccogli M, et al. A Non-Invasive Method for Detection of Antihypertensive Drugs in Biological Fluids: The Salivary Therapeutic Drug Monitoring. Front Pharmacol. 2022 Jan 5;12. Mamina O, Kabachny V. Identification and quantitative determination of clonidine by HPLC method. ScienceRise: Pharmaceutical Science. 2020;27(5):30–6. Qin J, Wang L, Wu L, Chen J, Shen T, Li Y, et al. Development of an LC-MS/MS method for determining the pharmacokinetics of clonidine following oral administration of Zhenju antihypertensive compound. Biomedical Chromatography. 2015 Jul 1;29(7):1068–75. Tang F, Bada H, Ng CM, Leggas M. Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma. Biomedical Chromatography. 2019 Jul 1;33(7). Veigure R, Aro R, Metsvaht T, Standing JF, Lutsar I, Herodes K, et al. A highly sensitive method for the simultaneous UHPLC–MS/MS analysis of clonidine, morphine, midazolam and their metabolites in blood plasma using HFIP as the eluent additive. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 1;1052:150–7. AlRabiah H, Attia SM, Al-Shakliah NS, Mostafa GAE. Development and validation of an HPLC-UV detection Assay for the determination of clonidine in mouse plasma and its application to a pharmacokinetic study. Molecules. 2020 Sep 1;25(18). Rayala VVSPK, Panda SR, Radhakrishnanand P. Pharmacokinetic, Protein Binding, and Tissue Distribution Investigations of Viloxazine Enantiomers in Rat Plasma by HPLC–MS/MS Using Polysaccharide-Based Immobilized Chiral Column: A Preclinical Approach to Possible Chiral Switch. Chromatographia. 2023 Dec 1;86(11–12):751–64. Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry. 2019;56:14–34. Accioni F, García-Gómez D, Girela E, Rubio S. SUPRAS extraction approach for matrix-independent determination of amphetamine-type stimulants by LC-MS/MS. Talanta. 2018 May 15;182:574–82. López-García E, Mastroianni N, Postigo C, Valcárcel Y, González-Alonso S, Barceló D, et al. Simultaneous LC–MS/MS determination of 40 legal and illegal psychoactive drugs in breast and bovine milk. Food Chem [Internet]. 2018;245(September 2017):159–67. Available from: https://doi.org/10.1016/j.foodchem.2017.10.005 Marchei E, Farré M, Pardo R, Garcia-Algar O, Pellegrini M, Pacifici R, et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin Chem. 2010 Apr 1;56(4):585–92. Comiran E, Carlos G, Barreto F, Pechanksy F, Fröehlich PE, Limberger RP. Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine. Biopharm Drug Dispos. 2021 Jan 1;42(1):3–11.